Polyrizon Ltd.
NASDAQPLRZ enters the back half of May with a clinical catalyst in hand — and a borrow market that has swung from near-maximum tightness to near-total availability in the space of a fortnight. The catalyst is concrete. Polyrizon signed a clinical trial agreement this week with a U.S. research site specialising in allergy studies, advancing its NASARIX allergy-blocker programme. That…
PLRZ short interest surges 61.6% in one week to 40,786 shares, driven by extreme borrowing costs at 406.8% APR and 77.7% utilization.
Snapshot as of 28 Jun 2026
PLRZ enters the back half of May with a clinical catalyst in hand — and a borrow market that has swung from near-maximum tightness to near-total availability in the space of a fortnight. The catalyst is concrete.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PLRZ — free to start on ORTEX.
Sign up for free →Open PLRZ on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live PLRZ data →